

| THERAPEUTIC AREA | PRODUCT | INDICATION | API MICRONIZED | CEP/DMF |
|---|--|--|----------------|------------------------|
| Antiallergics | Loratadine ^P | Allergy | √ | JP DMF |
| Antiarrhythmics | Dronedaron ^P | Atrial fibrillation & general arrhythmia | | DMF |
| Antiasthmatics, COPD and respiratory diseases | Arformoterol tartrate ^P polymorph A and D | COPD | | US-CN DMF |
| | Formoterol fumarate | Asthma and COPD | √ | CEP/US-JP-KR-CN-RU DMF |
| | Glycopyrronium bromide ^P | COPD | √ | CEP/ US-CN-KR-RU DMF |
| | Indacaterol maleate ^P | Asthma and COPD | √ | EU/US-KR-RU DMF |
| | Montelukast sodium ^P | Asthma, allergic & seasonal rhinitis | | EU-JP DMF |
| | Salmeterol xinafoate ^P | Asthma and COPD | √ | CEP/ US-CN-KR DMF |
| | Tiotropium Bromide | COPD | √ | CEP/US-CN DMF |
| | Vilanterol Trifenatate | Asthma and COPD | √ | EU/US DMF |
| Antiemetics | Aprepitant | Emesis | | US DMF |
| | Granisetron base ^P | Emesis | | US DMF |
| | Granisetron hydrochloride ^P | Emesis | | CEP/ US-JP-KR DMF |
| | Ondansetron base ^P | Emesis | √ | EU-US DMF |
| | Ondansetron hydrochloride ^P | Emesis | √ | CEP/US DMF |
| Antifungals | Fluconazole ^P | Antifungal | | CEP/US-KR DMF |
| Antihypertensive | Carvedilol ^P | Hypertension, angina, heart failure | | JP DMF |
| | Clevidipine ^P | Hypertension | | US DMF |
| | Enalapril maleate ^P | Hypertension | | CEP/KR DMF |
| | Imidapril | Hypertension | | EU DMF |
| | Nitrendipine | Hypertension | √ | CEP/DMF |
| Antimigrainics | Eletriptan HBr ^P | Migraine | √ | JP DMF |
| | Rizatriptan benzoate ^P | Migraine | √ | EU-US DMF |
| | Zolmitriptan ^P | Migraine | √ | EU-US DMF |
| Antiparkinson | Tetrabenazine | Huntington's disease chorea and Tardive dyskinesia | | EU-US DMF |
| Antipsychotics | Asenapine maleate ^P | Schizophrenia and acute mania | √ | JP DMF |
| | Olanzapine ^P | Schizophrenia, psychosis | | EU-US- DMF |
| | Quetiapine hemifumarate ^P | Schizophrenia, psychosis | | JP-KR DMF |
| | Risperidone ^P | Schizophrenia, psychosis | √ | CEP/US-KR DMF |
| Anti-thrombotics | Prasugrel base ^P | Prophylaxis and therapy of thrombosis | | EU DMF |
| | Rivaroxaban | Thrombosis. Stroke | | DMF |
| Spasmolytic | Otilonium bromide | Irritable bowel syndrome | | EU DMF |

CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

| THERAPEUTIC AREA | PRODUCT | INDICATION | SAMPLES | TECHNICAL PACKAGE | VALIDATION BATCH | DMF |
|---|-------------------------------|---------------------------|---------|-------------------|------------------|---------|
| Antiasthmatics, COPD and respiratory diseases | Aclidinium bromide | COPD | √ | √ | √ | Q4 2021 |
| | Olodaterol^P | COPD | √ | √ | √ | Q1 2023 |
| | Indacaterol acetate | Asthma | Q4 2021 | Q2 2022 | Q3 2022 | Q2 2023 |
| | Revefenacin | COPD | √ | √ | Q4 2021 | Q3 2022 |
| | Umeclidinium bromide | COPD | √ | √ | Q4 2021 | Q3 2022 |
| Antiparkinson | Benserazide | Parkinson's disease | √ | √ | Q4 2021 | Q3 2022 |
| Other disorders | Tafamidis meglumine | Transthyretin amyloidosis | √ | √ | √ | Q1 2022 |

CEP = Products with Certificate of Suitability

P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular, these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.